학술논문
Immune‐mediated thrombotic thrombocytopenic purpura in a Jehovah's Witness – Effectiveness of incorporating extracorporeal immunoadsorption to caplacizumab, steroids and rituximab.
Document Type
Article
Author
Source
Subject
*JEHOVAH'S Witnesses
*PLASMA exchange (Therapeutics)
*IMMUNOADSORPTION
*RITUXIMAB
*THROMBOTIC thrombocytopenic purpura
*IDIOPATHIC thrombocytopenic purpura
*TREATMENT effectiveness
*
*
*
*
*
*
Language
ISSN
2050-0904
Abstract
We report the case of a Jehovah's Witness adolescent patient with immune‐mediated thrombotic thrombocytopenic purpura after SARS‐Cov2 infection successfully treated without therapeutic plasma exchange (TPE) using caplacizumab, corticosteroids, rituximab, and extracorporeal immunoadsorption (EIA). Further patients for whom TPE is not an option might benefit from this approach. Our experience in this case suggests that caplacizumab together with corticosteroids, rituximab, and EIA may be an effective treatment option for further patients with i‐TTP who are unable to undergo TPE. EIA is as a treatment in place of TPE contributing to a very rapid removal of autoantibodies against ADAMTS‐13. [ABSTRACT FROM AUTHOR]